Video
ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
First-line osimertinib in EGFR mutant aNSCLC patients: Progression pattern and s...
Dr Martina Lorenzi - University of Padua, Padua, Italy
AMG 757: DLL3 targeting, half-life extended bispecific T-cell engager immuno-onc...
Dr Luis Paz-Ares - Hospital Universitario 12 de Octubre, Madrid, Spain
CheckMate 816 trial: Nivolumab and platinum-doublet chemotherapy vs chemo as neo...
Dr Patrick M. Forde - Johns Hopkins University, Baltimore, USA
Phase III randomised trial comparing tebentafusp with investigator’s choice in f...
Dr Jessica Hassel - University Hospital Heidelberg, Heidelberg, Germany
Randomised phase III study of copanlisib plus rituximab vs rituximab/placebo in ...
Dr Matthew Matasar - Memorial Sloan Kettering Cancer Center, NYC, US
PC14586: The first orally bioavailable small molecule reactivator of Y220C mutan...
Dr Melissa Dumble - PMV Pharmaceuticals, Cranbury, USA
First-line pembrolizumab plus chemotherapy for patients with advanced squamous N...
Dr Andrew Robinson - Cancer Centre of Southeastern Ontario at Kingston General H...
MERMAID-2: Phase 3 study of durvalumab in patients with resected stage MRD II-I...
Dr David Spigel - Sarah Cannon Research Institute, Nashville, USA
IMpower133: Exploratory analysis of maintenance therapy in patients with exten...
Prof Martin Reck and Dr Antonio Passaro
Incorporating KRAS as a novel biomarker: Challenges and opportunities
Prof Ales Ryska - Charles University, Prague, Czech Republic
Real world data and diagnostics in patients with NSCLC with EGFR exon 20 inserti...
Prof Nicolas Girard, Prof Keith Kerr, Prof Frank Griesinger and Dr Antonio Passa...
Challenges and solutions in PD-L1 testing in NSCLC
Prof Frédérique Penault-Llorca - Centre Jean Perrin, Clermont-Ferrand, France